Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Debt / NOTE 2.000% 8/1
-
Number of holders
-
20
-
Total 13F principal, excl. options
-
226,483,400
-
Principal change
-
+3,829,400
-
Total reported value, excl. options
-
$183,384,428
-
Value change
-
+$3,384,778
-
Number of buys
-
6
-
Number of sells
-
-6
-
Price
-
$0.8082
Significant Holders of AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q2 2017
23 filings reported holding 00767EAB8 - AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q2 2017.
AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 has 20 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $226,483,400 of principal
.
Largest 10 bondholders include EdgePoint Investment Group Inc. ($42,642,000 of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($35,000,000 of principal), Allianz Asset Management GmbH ($28,680,000 of principal), UBS OCONNOR LLC ($26,000,000 of principal), DEERFIELD MANAGEMENT CO ($16,600,000 of principal), ORBIMED ADVISORS LLC ($15,000,000 of principal), BAKER BROS. ADVISORS LP ($14,517,000 of principal), Tekla Capital Management LLC ($13,000,000 of principal), AMERIPRISE FINANCIAL INC ($12,460,000 of principal), and CITADEL ADVISORS LLC ($5,000,000 of principal).
This table shows the top 20 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.